Navigation Links
Satraplatin in Medical News

Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial

- Overall survival results do not achieve statistical significance - GPC Biotech schedules conference call for Wednesday, October 31st, 8:30 AM ET/13:30 CET BOULDER, Colo., MARTINSRIED, Germany, MUNICH, Germany and PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ ...

GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial

... announced that the Phase 3 SPARC trial evaluating satraplatin for the treatment of hormone-refractory prostate c...taxel, RenaZorb(TM), SPI-1620 and SPI-205." About satraplatin In 2002, Spectrum licensed the global rights to G...a Co., Ltd. Spectrum licensed worldwide rights to satraplatin from Johnson Matthey PLC. About Spectrum Pharmace...

Satraplatin Benefits Hormone Refractory Prostate Cancer Patients

...ort from Columbia University on Phase III trial on satraplatin has shown: * Highly Statistically Significant ... Chemotherapy Treatment, including Taxotere? * satraplatin was Well Tolerated with Myelosuppression the Most ..., all of which require intravenous administration, satraplatin is an orally bioavailable compound and is given as...
Satraplatin in Medical Technology

Additional Data From Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress

Patients treated with Satraplatin Demonstrated Statistically Significant Improvement in Pain Response and PSA Response Rates BERLIN, March 22, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation and GPC Biotech AG today announced additional data from the double-blind, randomized satraplatin Phase ...

Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association

-- Median time to pain progression is 66.1 weeks for the satraplatin arm compared with 22.3 weeks for the placebo arm -- Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representing a 36% reduction in the relative risk of pain progression MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-Fi...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

- All pre-specified subset analyses of progression-free survival in the SPARC Phase 3 trial consistently demonstrate a reduction in relative risk of disease progression for patients receiving satraplatin. These analyses included prior Taxotere use, geographies, as well as presence or absence of pai...

Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting

-- All pre-specified subset analyses of progression-free survival in the SPARC Phase 3 trial consistently demonstrate a reduction in relative risk of disease progression for patients receiving satraplatin. These analyses included prior Taxotere use, geographies, as well as presence or absence of pa...

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

...istic Interaction between the Oral Platinum Analog satraplatin and Erlotinib In preclinical studies, satraplatin was active in a number of various tumor models and... lines to satraplatin was examined. Conclusion satraplatin is synergistic with erlotinib, which may be relate...

Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting

...esented or published, including Phase III data for satraplatin and Thalidomide, encouraging Phase II data for Amr...pm; McCormick Place Convention Center, S Hall A2 satraplatin Oral Presentation: satraplatin demonstrates significant clinical benefits for the...
Satraplatin in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Cellular Immunotherapy II-59 Spectrum Announces Positive Outcome of satraplatin Trial on HRPC Patients II-59 Panacea Pharmaceuticals Identifies Blo...plera Corporation II-69 GPC Biotech and Celgene Terminate Agreement for satraplatin II-70 EUSA Acquires Cytogen Corporation II-70 Eisai Acquires MGI Ph...

Pharmion Corporation Announces 2007 Operating Results

...1, 2007 include a charge of $8 million for a milestone payment triggered by the acceptance of Pharmion's marketing authorization application (MAA) for satraplatin for the treatment of second-line hormone-refractory prostate cancer by the European Medicines Agency (EMEA). Research and development expenses total...

Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP

...tudies; (2) that the Company continued to evaluate satraplatin using the disputed endpoint; (3) that the Company ... with the disputed primary endpoint supporting its satraplatin New Drug Application ("NDA"); (4) that the FDA's e...h the NDA would not allow the FDA to conclude that satraplatin was more effective than placebo in terms of overal...

Finkelstein Thompson LLP Announces GPC Biotech AG Investigation

...Complaint further alleges that, under increased pressure to gain FDA marketing approval, Defendants used improper testing methods to determine whether satraplatin was safe and effective. On July 24, 2007, the FDA disclosed that it had unanimously recommended against the approval of Satraplatin. The market respo...
Other Tags
(Date:3/2/2015)... (PRWEB) March 02, 2015 Ticket Down ... at the Hollywood Bowl . This popular site has ... appreciation promo code JIMMY-BUFFETT-2015 for added savings. , Parrotheads ... favorite performer will be headlining at the Hollywood Bowl ... will be on Thursday, October 22nd and it will ...
(Date:3/2/2015)... Raleigh, NC (PRWEB) March 02, 2015 ... response can be a better predictor of outcomes for ... here to read details of the new study ... and pathologists at the University of Eastern Piedmont followed ... underwent talc pleurodesis treatment for excess lung fluid. ...
(Date:3/2/2015)... Burns Engineering's Lab-to-Lab Calibration Service ... Standard Platinum Resistance Thermometers (SSPRTs) and industrial Resistance ... less . . . guaranteed. Their ... Code 200706-0), ISO 9001 and 17025 Certified and ... -196°C to 500°C, both ITS-90 and Callendar-van Dusen ...
(Date:3/2/2015)... 2015 The minimally invasive surgical ... CAGR of 6.1% to reach $14,133.0 million by ... Factors such as advantages of minimally invasive surgeries ... to minimally invasive surgeries and increasing number of ... the global minimally invasive surgical instruments market. , ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Four Seasons Resort ... celebrating its 25th anniversary this year, having officially opened its ... the luxury resort is honoring over 70 employees who started ... -- from amongst the approximately 400 original employees. The ... Resort’s Oceanfront Lawn. , This Four Seasons flagship ...
Breaking Medicine News(10 mins):Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Celebrating Four Seasons Resort Maui’s 25th Anniversary 2
(Date:3/2/2015)... --  Neurotechnology , a provider of high-precision biometric, robotics ... Development Kit (SDK). The SentiGaze algorithm enables designers ... to track eye movements and generate heatmaps based on ... be used for applications such as analysis of websites ... can also be used to develop interfaces for a ...
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2
Other Contents